US Stock MarketDetailed Quotes

EBS Emergent BioSolutions

Watchlist
  • 9.120
  • +0.060+0.66%
Close Nov 1 16:00 ET
  • 9.120
  • 0.0000.00%
Post 20:01 ET
482.51MMarket Cap-812P/E (TTM)

Emergent BioSolutions Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
141.52%47.5M
65.98%-62.6M
-504.99%-206.3M
-65.41%32.1M
181.08%60M
-633.33%-114.4M
-393.30%-184M
-110.65%-34.1M
-71.72%92.8M
-543.11%-74M
Net income from continuing operations
-8.30%-283.1M
104.83%9M
-259.40%-760.5M
26.12%-49.5M
-211.72%-263.4M
-363.48%-261.4M
-4,932.43%-186.2M
-196.40%-211.6M
-137.66%-67M
-158.41%-84.5M
Operating gains losses
----
----
---74.2M
---3.7M
--4.4M
----
----
----
----
----
Depreciation and amortization
-13.37%28.5M
-19.36%27.9M
-12.70%125.1M
-17.09%29.6M
-13.04%28M
-26.07%32.9M
11.97%34.6M
15.75%143.3M
22.26%35.7M
-1.53%32.2M
Deferred tax
88.24%-200K
-159.57%-12.2M
68.88%-8.9M
90.39%-5.2M
-88.21%2.7M
-342.86%-1.7M
-347.37%-4.7M
-162.17%-28.6M
-219.16%-54.1M
502.63%22.9M
Other non cash items
28.11%23.7M
168.75%4.3M
163.36%34.5M
292.59%10.4M
-68.00%4M
374.36%18.5M
-23.81%1.6M
45.56%13.1M
93.86%-5.4M
-86.29%12.5M
Change In working capital
244.19%205.9M
-170.08%-97.5M
-3,247.62%-70.3M
-71.85%46.5M
190.92%62.1M
-593.20%-142.8M
53.95%-36.1M
98.55%-2.1M
28.16%165.2M
23.00%-68.3M
-Change in receivables
115.41%20.4M
-2,023.08%-50M
-118.29%-21.6M
3.65%36.9M
569.08%71.3M
-3,410.00%-132.4M
-97.23%2.6M
829.01%118.1M
-63.86%35.6M
81.00%-15.2M
-Change in inventory
-324.14%-13M
85.34%-4.5M
101.05%600K
-43.98%25.6M
99.63%-100K
122.83%5.8M
38.72%-30.7M
14.26%-57.1M
631.40%45.7M
-225.81%-27.3M
-Change in prepaid assets
1,348.12%166M
-33.33%-6M
158.79%11.7M
108.33%30M
96.64%-500K
-375.00%-13.3M
72.89%-4.5M
-358.44%-19.9M
-76.96%14.4M
71.56%-14.9M
-Change in payables and accrued expense
532.88%31.6M
-332.50%-34.6M
31.90%-55.5M
-170.51%-42.2M
125.64%2M
-118.34%-7.3M
91.83%-8M
-1,098.53%-81.5M
-177.61%-15.6M
-118.62%-7.8M
-Change in other working capital
-79.55%900K
-153.33%-2.4M
-114.36%-5.5M
-104.47%-3.8M
-241.94%-10.6M
112.15%4.4M
160.00%4.5M
160.70%38.3M
295.18%85.1M
84.42%-3.1M
Cash from discontinued investing activities
Operating cash flow
141.52%47.5M
65.98%-62.6M
-504.99%-206.3M
-65.41%32.1M
181.08%60M
-633.33%-114.4M
-393.30%-184M
-110.65%-34.1M
-71.72%92.8M
-543.11%-74M
Investing cash flow
Cash flow from continuing investing activities
-101.79%-4.6M
28.48%-10.8M
155.68%212.3M
74.89%-11.4M
93.04%-18.9M
902.80%257.7M
53.11%-15.1M
-70.15%-381.3M
0.87%-45.4M
-392.03%-271.6M
Net PPE purchase and sale
63.20%-4.6M
28.48%-10.8M
55.44%-51.6M
51.69%-11.4M
54.84%-12.6M
61.06%-12.5M
53.11%-15.1M
48.33%-115.8M
48.47%-23.6M
49.46%-27.9M
Net business purchase and sale
----
----
--270.2M
--0
--0
----
----
--0
--0
--0
Net other investing changes
----
----
97.63%-6.3M
--0
----
----
----
---265.5M
---21.8M
----
Cash from discontinued investing activities
Investing cash flow
-101.79%-4.6M
28.48%-10.8M
155.68%212.3M
74.89%-11.4M
93.04%-18.9M
902.80%257.7M
53.11%-15.1M
-70.15%-381.3M
0.87%-45.4M
-392.03%-271.6M
Financing cash flow
Cash flow from continuing financing activities
89.55%-50.9M
487.62%40.7M
-211.33%-535.7M
-98.67%4.7M
-118.75%-43M
-1,485.99%-486.9M
85.11%-10.5M
441.28%481.2M
420.42%353.1M
4,686.00%229.3M
Net issuance payments of debt
90.83%-45.5M
589.29%41.1M
-196.31%-543.4M
-98.83%4.1M
-118.68%-42.9M
-5,807.14%-496.2M
1.18%-8.4M
1,671.59%564.2M
4,284.52%351.5M
4,200.00%229.6M
Net common stock issuance
----
----
110.23%8.4M
200.00%200K
--0
----
----
22.55%-82.1M
99.81%-200K
--0
Proceeds from stock option exercised by employees
----
----
-64.00%1.8M
-75.00%500K
--0
----
----
-68.55%5M
-41.18%2M
--0
Net other financing activities
-2,950.00%-6.1M
80.95%-400K
57.63%-2.5M
50.00%-100K
66.67%-100K
50.00%-200K
58.00%-2.1M
60.67%-5.9M
-120.00%-200K
84.21%-300K
Cash from discontinued financing activities
Financing cash flow
89.55%-50.9M
487.62%40.7M
-211.33%-535.7M
-98.67%4.7M
-118.75%-43M
-1,485.99%-486.9M
85.11%-10.5M
441.28%481.2M
421.00%353.1M
4,686.00%229.3M
Net cash flow
Beginning cash position
-81.64%79M
-82.62%111.7M
11.50%642.6M
-63.57%87.8M
-75.27%88.6M
-1.33%430.2M
11.50%642.6M
-7.27%576.3M
-40.35%241M
-19.97%358.3M
Current changes in cash
97.67%-8M
84.40%-32.7M
-905.02%-529.7M
-93.66%25.4M
98.37%-1.9M
-338.27%-343.6M
-49.71%-209.6M
246.55%65.8M
132.44%400.5M
-167.36%-116.3M
Effect of exchange rate changes
--0
--0
-340.00%-1.2M
-236.36%-1.5M
210.00%1.1M
-185.71%-600K
33.33%-200K
266.67%500K
--1.1M
-400.00%-1M
End cash Position
-19.86%71M
-81.64%79M
-82.62%111.7M
-82.62%111.7M
-63.57%87.8M
-75.27%88.6M
-1.33%430.2M
11.50%642.6M
11.50%642.6M
-40.35%241M
Free cash flow
133.81%42.9M
63.13%-73.4M
-72.05%-257.9M
-70.09%20.7M
146.52%47.4M
-166.04%-126.9M
-186.47%-199.1M
-255.98%-149.9M
-75.49%69.2M
-164.68%-101.9M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022(Q3)Sep 30, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 141.52%47.5M65.98%-62.6M-504.99%-206.3M-65.41%32.1M181.08%60M-633.33%-114.4M-393.30%-184M-110.65%-34.1M-71.72%92.8M-543.11%-74M
Net income from continuing operations -8.30%-283.1M104.83%9M-259.40%-760.5M26.12%-49.5M-211.72%-263.4M-363.48%-261.4M-4,932.43%-186.2M-196.40%-211.6M-137.66%-67M-158.41%-84.5M
Operating gains losses -----------74.2M---3.7M--4.4M--------------------
Depreciation and amortization -13.37%28.5M-19.36%27.9M-12.70%125.1M-17.09%29.6M-13.04%28M-26.07%32.9M11.97%34.6M15.75%143.3M22.26%35.7M-1.53%32.2M
Deferred tax 88.24%-200K-159.57%-12.2M68.88%-8.9M90.39%-5.2M-88.21%2.7M-342.86%-1.7M-347.37%-4.7M-162.17%-28.6M-219.16%-54.1M502.63%22.9M
Other non cash items 28.11%23.7M168.75%4.3M163.36%34.5M292.59%10.4M-68.00%4M374.36%18.5M-23.81%1.6M45.56%13.1M93.86%-5.4M-86.29%12.5M
Change In working capital 244.19%205.9M-170.08%-97.5M-3,247.62%-70.3M-71.85%46.5M190.92%62.1M-593.20%-142.8M53.95%-36.1M98.55%-2.1M28.16%165.2M23.00%-68.3M
-Change in receivables 115.41%20.4M-2,023.08%-50M-118.29%-21.6M3.65%36.9M569.08%71.3M-3,410.00%-132.4M-97.23%2.6M829.01%118.1M-63.86%35.6M81.00%-15.2M
-Change in inventory -324.14%-13M85.34%-4.5M101.05%600K-43.98%25.6M99.63%-100K122.83%5.8M38.72%-30.7M14.26%-57.1M631.40%45.7M-225.81%-27.3M
-Change in prepaid assets 1,348.12%166M-33.33%-6M158.79%11.7M108.33%30M96.64%-500K-375.00%-13.3M72.89%-4.5M-358.44%-19.9M-76.96%14.4M71.56%-14.9M
-Change in payables and accrued expense 532.88%31.6M-332.50%-34.6M31.90%-55.5M-170.51%-42.2M125.64%2M-118.34%-7.3M91.83%-8M-1,098.53%-81.5M-177.61%-15.6M-118.62%-7.8M
-Change in other working capital -79.55%900K-153.33%-2.4M-114.36%-5.5M-104.47%-3.8M-241.94%-10.6M112.15%4.4M160.00%4.5M160.70%38.3M295.18%85.1M84.42%-3.1M
Cash from discontinued investing activities
Operating cash flow 141.52%47.5M65.98%-62.6M-504.99%-206.3M-65.41%32.1M181.08%60M-633.33%-114.4M-393.30%-184M-110.65%-34.1M-71.72%92.8M-543.11%-74M
Investing cash flow
Cash flow from continuing investing activities -101.79%-4.6M28.48%-10.8M155.68%212.3M74.89%-11.4M93.04%-18.9M902.80%257.7M53.11%-15.1M-70.15%-381.3M0.87%-45.4M-392.03%-271.6M
Net PPE purchase and sale 63.20%-4.6M28.48%-10.8M55.44%-51.6M51.69%-11.4M54.84%-12.6M61.06%-12.5M53.11%-15.1M48.33%-115.8M48.47%-23.6M49.46%-27.9M
Net business purchase and sale ----------270.2M--0--0----------0--0--0
Net other investing changes --------97.63%-6.3M--0---------------265.5M---21.8M----
Cash from discontinued investing activities
Investing cash flow -101.79%-4.6M28.48%-10.8M155.68%212.3M74.89%-11.4M93.04%-18.9M902.80%257.7M53.11%-15.1M-70.15%-381.3M0.87%-45.4M-392.03%-271.6M
Financing cash flow
Cash flow from continuing financing activities 89.55%-50.9M487.62%40.7M-211.33%-535.7M-98.67%4.7M-118.75%-43M-1,485.99%-486.9M85.11%-10.5M441.28%481.2M420.42%353.1M4,686.00%229.3M
Net issuance payments of debt 90.83%-45.5M589.29%41.1M-196.31%-543.4M-98.83%4.1M-118.68%-42.9M-5,807.14%-496.2M1.18%-8.4M1,671.59%564.2M4,284.52%351.5M4,200.00%229.6M
Net common stock issuance --------110.23%8.4M200.00%200K--0--------22.55%-82.1M99.81%-200K--0
Proceeds from stock option exercised by employees ---------64.00%1.8M-75.00%500K--0---------68.55%5M-41.18%2M--0
Net other financing activities -2,950.00%-6.1M80.95%-400K57.63%-2.5M50.00%-100K66.67%-100K50.00%-200K58.00%-2.1M60.67%-5.9M-120.00%-200K84.21%-300K
Cash from discontinued financing activities
Financing cash flow 89.55%-50.9M487.62%40.7M-211.33%-535.7M-98.67%4.7M-118.75%-43M-1,485.99%-486.9M85.11%-10.5M441.28%481.2M421.00%353.1M4,686.00%229.3M
Net cash flow
Beginning cash position -81.64%79M-82.62%111.7M11.50%642.6M-63.57%87.8M-75.27%88.6M-1.33%430.2M11.50%642.6M-7.27%576.3M-40.35%241M-19.97%358.3M
Current changes in cash 97.67%-8M84.40%-32.7M-905.02%-529.7M-93.66%25.4M98.37%-1.9M-338.27%-343.6M-49.71%-209.6M246.55%65.8M132.44%400.5M-167.36%-116.3M
Effect of exchange rate changes --0--0-340.00%-1.2M-236.36%-1.5M210.00%1.1M-185.71%-600K33.33%-200K266.67%500K--1.1M-400.00%-1M
End cash Position -19.86%71M-81.64%79M-82.62%111.7M-82.62%111.7M-63.57%87.8M-75.27%88.6M-1.33%430.2M11.50%642.6M11.50%642.6M-40.35%241M
Free cash flow 133.81%42.9M63.13%-73.4M-72.05%-257.9M-70.09%20.7M146.52%47.4M-166.04%-126.9M-186.47%-199.1M-255.98%-149.9M-75.49%69.2M-164.68%-101.9M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion with Explanatory Notes--------Unqualified Opinion with Explanatory Notes----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept Mpox (monkeypox)
Mpox (monkeypox)
Intraday+2.24%